US Stock Insider Trading | AbbVie disclosed one insider trading transaction on March 11

K-LinePoet · 2026-03-12T08:06:12+00:00

AbbVie recently disclosed insider trading activities involving several executives, mainly between February 27, 2026, and March 4, 2026. Several executives, such as Purdue David Ryan, sold shares, with total transaction amounts reaching millions of dollars. The company focuses on developing biopharmaceuticals to treat complex diseases, with a promising outlook.

K-LinePoet

2026-03-12 08:06:12

Abstract generation in progress

On March 11, 2026, AbbVie (ABBV) disclosed an insider transaction. Executive Purdue David Ryan sold 2,108 shares on February 27, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 11, 2026	Executive	Purdue David Ryan	February 27, 2026	Sell	2,108	232.08	$489,200
March 6, 2026	Executive	Purdue David Ryan	March 4, 2026	Sell	5,230	233.56	$1,221,500
March 6, 2026	Executive	Crum Demetris D	February 27, 2026	Sell	1,594	232.08	$369,900
March 3, 2026	Executive	Reents Scott T	February 27, 2026	Sell	21,600	232.08	$5,021,700
March 3, 2026	Executive	Donoghoe Nicholas	February 27, 2026	Sell	12,900	232.08	$2,987,800
March 3, 2026	Executive	Stewart Jeffrey Ryan	February 27, 2026	Sell	23,800	232.08	$5,526,300
March 3, 2026	Executive	Siatis Perry C	March 2, 2026	Sell	5,777	233.51	$1,349,000
March 3, 2026	Executive	SALEKI-GERHARDT AZITA	February 27, 2026	Sell	16,300	232.08	$3,785,000
March 3, 2026	Director	Michael Robert A.	February 27, 2026	Sell	36,500	232.08	$8,476,300
March 3, 2026	Executive	Siatis Perry C	February 27, 2026	Sell	14,900	232.08	$3,446,400

[Company Profile]

AbbVie was incorporated on April 10, 2012, in Delaware, holding the research-based pharmaceutical business formerly owned by Abbott. The company is a global, research-driven biopharmaceutical company. AbbVie develops and markets advanced therapies to address some of the world’s most complex and serious diseases. Its products focus on treating chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease; low testosterone; HIV; endometriosis; thyroid disorders; Parkinson’s disease; and complications related to chronic kidney disease and cystic fibrosis. AbbVie’s promising pipeline includes over 20 compounds or indications in Phase II or III development, covering key medical fields such as immunology, virology, oncology, nephrology, neurology, and women’s health.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.